Blau Farmaceutica (BSP:BLAU3) EBIT : R$378 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Blau Farmaceutica EBIT?

Blau Farmaceutica's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was R$295 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was R$378 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Blau Farmaceutica's annualized ROC % for the quarter that ended in Dec. 2023 was 45.73%. Blau Farmaceutica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 75.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Blau Farmaceutica's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 17.82%.

Blau Farmaceutica EBIT Historical Data

The historical data trend for Blau Farmaceutica's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blau Farmaceutica EBIT Chart

Blau Farmaceutica Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

301.48

368.96

509.26

500.99

366.34

Blau Farmaceutica Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															126.19	63.75	97.96	-79.20	295.09

Competitive Comparison of Blau Farmaceutica's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blau Farmaceutica's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Blau Farmaceutica's EV-to-EBIT falls into.

Blau Farmaceutica EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$378 Mil.

Blau Farmaceutica (BSP:BLAU3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Blau Farmaceutica's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	1133.316 * ( 1 - 3.98% )	/	( (2328.043	+	2431.748)	/ 2 )
=	1088.2100232	/	2379.8955
=	45.73 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3074.044	-	274.061	-	( 471.94	-	max(0, 472.397	-	1626.55	+	471.94	))
=	2328.043

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3053.528	-	214.466	-	( 407.314	-	max(0, 335.926	-	1553.869	+	407.314	))
=	2431.748

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Blau Farmaceutica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1180.34	/	( ( (722.335 + max(793.254, 0))	+	(745.875 + max(885.417, 0)) )	/	2 )
=	1180.34	/	( ( 1515.589	+	1631.292 )	/	2 )
=	1180.34	/	1573.4405
=	75.02 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(433.469	+	648.049	+	45.752)	-	(274.061	+	0	+	59.955)
=	793.254

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(453.329	+	628.646	+	64.35)	-	(214.466	+	0	+	46.442)
=	885.417

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Blau Farmaceutica's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	377.6	/	2118.399
	=	17.82 %

Blau Farmaceutica EBIT Related Terms

Thank you for viewing the detailed overview of Blau Farmaceutica's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Blau Farmaceutica (BSP:BLAU3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blau Farmaceutica SA (BSP:BLAU3) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rodovia Raposo Tavares, No. 2833, Km 30.5, Barro Branco, Cotia, SP, BRA, 06705-030

Website

https://www.blau.com

Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.

Blau Farmaceutica (BSP:BLAU3) Headlines

No Headlines